Title of the Post Goes Here

The European Heart Rhythm Association (EHRA) and the European Society of Cardiology has issued a new “practical guide” for the use of anticoagulant medications for the treatment of AF. The new guide helps to map out differences that exist between the “four new agents and special considerations in their use in different clinical settings.”

This new guideline is currently published online in the European Heart Journal and Europace. The four newer anticoagulant medications discussed in the new guide include Dabigatran, Rivaroxaban, Apixaban and Andedoxaban. This new document still has to be approved by the FDA and the European Medicines Agency. In the guide, there are 15 “topics of concrete clinical scenarios” presented and each of them contains various lesson plans that are based on clinical trial data and other “available knowledge” about how to use each drug. For the topics brought up, each of them explains the use of the four agents that will provide the AF patients with the best possible results. A good example of this is found in the area that interprets anticoagulation assays notes that “it is paramount to know exactly when the [agent] was administered relative to the time of blood sampling.”

One medication that is not mentioned in the document, however, is Multaq, another anticoagulant made by Sanofi-Aventis. Multaq has been linked to serious side effects including a worsening of the heart condition, liver failure and lung toxicity. The drug is not recommended by the FDA for use unless all other medications fail.

If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.

Share this article

You May Also Like

All Rights Reserved 2016